Literature DB >> 11159541

Human peripheral blood eosinophils express stem cell factor.

M Hartman1, A M Piliponsky, V Temkin, F Levi-Schaffer.   

Abstract

Stem cell factor (SCF) or c-Kit ligand is a cytokine associated with the differentiation, survival, and activation of mast cells. Eosinophils have pleiotropic functions in several diseases and, together with mast cells, are key cells in allergy. Mast cell-eosinophil interactions can take place during the late and chronic phases of allergy. It was, therefore, investigated whether eosinophils can produce SCF and consequently influence mast cells. Human peripheral blood eosinophils variably expressed mRNA for the soluble and uncleaved forms of SCF (reverse transcription-polymerase chain reaction) and produced the 18.5-kd protein backbone of SCF (Western blot analysis). After overnight incubation in medium, eosinophils also produced SCF of higher molecular weight (42-45 kd) that might represent its glycosylated forms. Eosinophils expressed cytoplasmic SCF that colocalized with major basic protein (confocal laser microscopy). Freshly isolated eosinophils contained 8.9 +/- 1.7 pg SCF/10(6) (mean +/- SEM; enzyme-linked immunosorbent assay). Although overnight incubation of the eosinophils in either culture medium or in phorbol 12-myristate 13-acetate-calcium ionophore did not cause the secretion of SCF, the addition of chymase induced SCF release. In summary, it was demonstrated that human peripheral blood eosinophils are a source of SCF. These results may contribute to a better understanding of the interactions between eosinophils and mast cells in allergic inflammation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11159541     DOI: 10.1182/blood.v97.4.1086

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

Review 1.  Mechanisms of eosinophil cytokine release.

Authors:  Christianne Bandeira-Melo; Peter F Weller
Journal:  Mem Inst Oswaldo Cruz       Date:  2005-06-14       Impact factor: 2.743

Review 2.  Mechanisms of eosinophil secretion: large vesiculotubular carriers mediate transport and release of granule-derived cytokines and other proteins.

Authors:  Rossana C N Melo; Lisa A Spencer; Ann M Dvorak; Peter F Weller
Journal:  J Leukoc Biol       Date:  2007-09-17       Impact factor: 4.962

3.  Inflamed juvenile conjunctival naevus: clinicopathological characterisation.

Authors:  Ehud Zamir; Hadas Mechoulam; Alessandra Micera; Francesca Levi-Schaffer; Jacob Pe'er
Journal:  Br J Ophthalmol       Date:  2002-01       Impact factor: 4.638

Review 4.  Synergy of Interleukin (IL)-5 and IL-18 in eosinophil mediated pathogenesis of allergic diseases.

Authors:  Hemanth Kumar Kandikattu; Sathisha Upparahalli Venkateshaiah; Anil Mishra
Journal:  Cytokine Growth Factor Rev       Date:  2019-05-10       Impact factor: 7.638

Review 5.  Human eosinophils and mast cells: Birds of a feather flock together.

Authors:  Piper A Robida; Pier Giorgio Puzzovio; Hadas Pahima; Francesca Levi-Schaffer; Bruce S Bochner
Journal:  Immunol Rev       Date:  2018-03       Impact factor: 12.988

6.  Intragranular vesiculotubular compartments are involved in piecemeal degranulation by activated human eosinophils.

Authors:  Rossana C N Melo; Sandra A C Perez; Lisa A Spencer; Ann M Dvorak; Peter F Weller
Journal:  Traffic       Date:  2005-10       Impact factor: 6.215

7.  Intranasal sirna targeting c-kit reduces airway inflammation in experimental allergic asthma.

Authors:  Wei Wu; Hui Chen; Ya-Ming Li; Sheng-Yu Wang; Xin Diao; Kai-Ge Liu
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

Review 8.  Mast cells and eosinophils: the two key effector cells in allergic inflammation.

Authors:  Yael Minai-Fleminger; Francesca Levi-Schaffer
Journal:  Inflamm Res       Date:  2009-05-08       Impact factor: 4.575

Review 9.  ADAM8: a new therapeutic target for asthma.

Authors:  Martin D Knolle; Caroline A Owen
Journal:  Expert Opin Ther Targets       Date:  2009-05       Impact factor: 6.902

10.  Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects.

Authors:  Christoph Mundhenke; Marion Tina Weigel; Klarissa Hanja Sturner; Frank Roesel; Ivo Meinhold-Heerlein; Dirk O Bauerschlag; Christian Schem; Felix Hilpert; Walter Jonat; Nicolai Maass
Journal:  J Cancer Res Clin Oncol       Date:  2008-05-09       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.